CBX

 CSPC Pharmaceutical is conducting a phase 2 study (CTR20241075) for nonsegmental vitiligo of SYHX1901, an oral JAK/SYK inhibitor. The first phase 2 study for psoriasis began in March 2023.  The first-in-human study, initiated in healthy participants in 2021, has been completed in 2022. The study was aimed at patients with SLE and RA. SYHX1901 SYHX1901 is a dual inhibitor of JAK and SYK, expected to be effective in treating autoimmune diseases such as psoriasis, lupus, and vitiligo. In 2023, CSPC filed a patent (WO2022188796) covering the use of a compound containing a tricyclic heteroaryl group for the treatment of autoimmune disease.  2021 Patent The IC 50 values for the compound I were measured against JAK1, JAK2, JAK3, TYK2, and SYK, yielding values of 20.04 nM, 3.92 nM, 1.43 nM, 0.82 nM, and 7.25 nM, respectively. Efficacies for psoriasis, atopic dermatitis, and SLE were tested in the IMQ-induced model, OXA-induced model, and SLE model mice.  Efficacy results in SLE model Accordi